NY-BALLERINE
23.5.2023 14:31:34 CEST | Business Wire | Press release
Ballerine, an open-source risk decisioning platform, has raised $5 Million in a seed funding round led by Team8. The company provides an open-source platform that integrates global data sources, along with the necessary tools to automate and enhance decision-making processes for tasks such as onboarding (KYB), underwriting, and transaction monitoring. Ballerine caters to any business handling financial transactions subjected to KYB, KYC, and anti-money laundering regulations, including most financial institutions, FinTechs, e-commerce, marketplaces, and other businesses. Ballerine is experiencing rapid growth and traction, its open-source GitHub repository has attracted over 1500 developers worldwide, with dozens of fintech companies using its code in production.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005284/en/
In order of appearance from left to right is: Nitzan Guy (Co-founder and CPO), Noam Izhaki (Co-founder and CEO), Alon Peretz (Co-founder and CTO). (Photo: Business Wire)
The company was founded by an expert team of developers from the digital banking space with extensive experience building in-house risk infrastructure, and a first-hand understanding of the many challenges associated with developing and maintaining risk systems internally. The founding team, Noam Izhaki (CEO), Nitzan Guy (CPO), and Alon Peretz (CTO), launched Ballerine to solve the pain points they encountered using a developer-first, open-source and modular approach.
Traditionally, verifying, underwriting and monitoring businesses is a complex task. It involves extensive data pulling from multiple sources, documentation, and policy updates due to changes in regulations, threats, and best practices. This complexity increases exponentially as companies expand to new geographies or add new products and business lines. Ballerine simplifies this task, enabling developers to fully customize their risk assessment workflow through a marketplace of point solutions. Data sources can be accessed via a single commercial agreement with Ballerine or through commercialization directly with data vendors. These sources include but are not limited to: company registries, sanctions, websites/social, credit agencies, adverse media, PEP databases, UBO registries and Open-Banking.
“The financial industry desperately needs infrastructure to support its ongoing digital transformation, infrastructure that empowers institutions to automatically access and analyze data throughout the customer journey," said Noam Izhaki, the CEO and Co-Founder of Ballerine, “Ballerine offers exactly that - it leverages dispersed data, simplifies privacy management, and empowers companies to continually enhance their risk-decisioning processes while maintaining control and flexibility.”
Ballerine's open-source core gives developers and risk managers control over the infrastructure with a single integration and allows customization to address specific needs around customer experience, risk exposures, audiences, and geographies. Ballerine’s open-source platform is the next-gen infrastructure for risk and identity decisioning as it offers significantly more flexibility for global financial services and large institutions, catering to many more use cases and leaving more room for customers to extend and customize the platform.
“Ballerine has a real opportunity to transform the way any business handling financial transactions manages risk.” said Hadar Siterman Norris, Partner at Team8. “This funding will help Ballerine create the first open-source and developer-centric compliance infrastructure, which is sure to propel Ballerine to even greater heights. We are excited to be part of their journey.”
The funding round was led by Team8 with participation from Y Combinator, Vera Equity and executives from Brex, Trulioo, Venmo, Melio and Coinbase. Ballerine and Team8 will be attending Money 20/20 in Amsterdam, June 6-8, 2023. Noam Izhaki, Ballerine’s CEO and Co-Founder, will be speaking at the conference during a presentation, “Open-Source is Coming: Watch Out Financial Services.” To learn more about Ballerine, visit: www.ballerine.com.
About Ballerine
Ballerine is an open-source platform that enables businesses offering financial products and services to verify and underwrite their customers globally or at scale. Their technology provides developers and risk managers with maximum control over compliance infrastructure with a single integration, and can be easily customized to address specific needs around customer experience, risk exposures, audiences, and geographies. Ballerine caters to any business handling financial transactions that are subject to KYB/KYC and money laundering regulations. This includes nearly all financial institutions and fintechs, as well as many eCommerce, marketplaces and SaaS companies. For more information, visit https://www.ballerine.com/
About Team8
Team8 is a venture group that builds and invests in the most innovative technologies in the fields of fintech, cyber, data, and digital health. We leverage deep domain expertise, cutting-edge technology, and first-hand company-building experience to partner with entrepreneurs in founding globally-successful companies, while also investing in early-stage companies that are active in the Group's fields of interest. Visit www.team8.vc to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005284/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
